Case Report
Copyright ©2007 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Apr 14, 2007; 13(14): 2135-2137
Published online Apr 14, 2007. doi: 10.3748/wjg.v13.i14.2135
A case of capecitabine-induced coronary microspasm in a patient with rectal cancer
Leire Arbea, Isabel Coma-Canella, Rafael Martinez-Monge, Jesús García-Foncillas
Leire Arbea, Rafael Martinez-Monge, Jesús García-Foncillas, Radiation Oncology Division, Department of Oncology, Clínica Universitaria, University of Navarra, Avda Pío XII s/n 31080, Spain
Isabel Coma-Canella, Department of Cardiology, Clínica Universitaria, University of Navarra, Avda Pío XII s/n 31080, Spain
Author contributions: All authors contributed equally to the work.
Correspondence to: Leire Arbea, MD, Radiation Oncology Division, Department of Oncology, Clínica Universitaria, University of Navarra, Avda, Pío XII s/n. 31080, Spain. larbea@unav.es
Telephone: +34-948-255400 Fax: +34-948-255500
Received: August 11, 2006
Revised: March 23, 2007
Accepted: March 31, 2007
Published online: April 14, 2007

Abstract

5-Fluorouracil (5-FU) is the most frequently used chemotherapy agent concomitant with radiotherapy in the management of patients with rectal cancer. Capecitabine is an oral fluoropyrimidine that mimics the pharmaconkinetics of infusional 5-FU. This new drug is replacing 5-FU as a part of the combined-modality treatment of a number of gastrointestinal cancers. While cardiac events associated with the use of 5-FU are a well known side effect, capecitabine-induced cardiotoxicity has been only rarely reported. Here, we reviewed the case of a patient with rectal cancer who had a capecitabine-induced coronary vasospasm. The most prominent mutation of the dihydropyrimidine dehydrogenase gene was also analyzed.

Key Words: Rectal cancer, Capecitabine, Cardiotoxicity


Citation: Arbea L, Coma-Canella I, Martinez-Monge R, García-Foncillas J. A case of capecitabine-induced coronary microspasm in a patient with rectal cancer. World J Gastroenterol 2007; 13(14): 2135-2137
INTRODUCTION

5-Fluorouracil (5-FU) is an antimetabolite that is widely used in the treatment of solid tumors. The metabolism and pharmacokinetics of 5-FU play important roles in determining its efficacy and toxicity. Cardiac events related to 5-FU have been described since 1975[1]. Recent prospective clinical trials have demonstrated that 2% to 10% of the patients exposed to 5-FU developed cardiovascular complications[2,3]. Capecitabine is a fluoropyrimidine carbamate active in several solid tumors. Its use will be probably increased in the coming years in patients with colorectal cancer due to the recent findings of a randomized trial[4]. This clinical trial demonstrated that capecitabine is an effective alternative to intravenous fluorouracil (5-FU) plus leucovorin in the adjuvant treatment of colon cancer. Capecitabne is converted to the active 5-FU by the action of a series of enzymes. One of these enzymes, thymidine phosphorylase (TP), has higher concentrations in tumor tissue than in normal tissue[5]. This suggests that the activation occurs preferentially in tumor tissue, providing a favorable ratio for toxicity and radiosensitization. Only a few cases of capecitabine-induced cardiotoxicity have been reported to date[6-10]. The first case described occurred in a patient with a prior history of 5-FU-related cardiotoxicity[7]. Another report described a case of coronary spasm after drug administration in a woman with moderate arterial hypertension[9]. To our knowledge, capecitabine-induced coronary vasospasm has been only once reported in patients without previous history of cardiologic events[8]. A common etiology for capecitabine and 5-FU-induced coronary vasospasm has recently been suggested in a colon cancer patient[6].

Walko et al recently compiled a review of the literature reporting adverse effects observed in capecitabine-treated patients[10]. Chest pain occurred in 6% of 758 breast and colorectal cancer patients treated with capecitabine at a dose of 2500 mg/m2 per day in 2 divided doses for 14 d followed by 1 wk rest. They concluded that this complication is more frequent in patients who have a history of coronary artery disease and recommended close monitoring for cardiac abnormalities during therapy.

The present case report describes several episodes of angina after oral administration of capecitabine in a patient without prior cardiac history and without previous treatment with fluoropyrimidines.

CASE REPORT

A 71 year-old male patient with a moderately differentiated adenocarcinoma of the rectum (uT3N0) was to be treated with intensity modulated radiation therapy (48, 34 Gy to the 95% of the Gross Tumor Volume) with Oxaliplatin 60 mg/m2 on d 1, 8 and 15 and Capecitabine 825 mg/m2 bid given on the radiation days. Surgery was to follow 4-6 wk later.

On March 16, 2005, the patient started radiotherapy; he received the first cycle of Oxaliplatin and was placed on Capecitabine. On radiation d 8, he received the second chemotherapy cycle without any complications. On d 9, he complained of stomach pain and nausea, and gastric protection and antiemetics were increased. On d 15, the third cycle of Oxaliplatin was given, and the patient continued with oral capecitabine. He continued to complain of the same stomach pain which improved with vomiting. On d 17 he came to the emergency room complaining of thoracic pressure, sweat, and dyspnea during exercise on two different occasions. He had had two previous episodes of chest pain at rest, and one of these episodes woke him up. A cardiac check-up was undertaken. The electrocardiogram showed no abnormalities. The echocardiogram demonstrated a normal systolic function with an ejection fraction of 0.55. During the stress echocardiography with exercise the patient had oppressive thoracic pain, ST segment elevation in precordial and inferior electrocardiographic leads (Figure 1) and contractility changes (akinesia and severe hypokinesia) in the territory of the right and anterior descending coronary arteries respectively. Cardiac catheterization did not reveal significant coronary artery disease and intracoronary injection of ergonovine failed to induce coronary spasm in the epicardial arteries. Capecitabine administration was discontinued, and the patient completed the planned irradiation course uneventfully.

Figure 1
Figure 1 EKG during the stress ecocardiography. ST elevation in anterior (V4-V6) and inferior leads (DII, DIII, aVF).

Dihydropyrimidine dehydrogenase (DPD) defficiency, which may cause accumulation of potentially cardiotoxic 5-FU metabolites, was ruled out. DNA was isolated from purified lymphocytes by standard procedures and PCR amplification of exon 14 and its flanking intronic regions was performed. Further sequence analysis was carried out on an Applied Biosystems model 377 automated DNA sequencer using the dye-terminator method. DNA sequence was clearly wild-type (Figure 2).

Figure 2
Figure 2 Wild-type sequence at 5'-splice recognition site of intron 14 in DPD gene.
DISCUSSION

Capecitabine is converted to 5´-deoxy-5-fluorocytudine (5'DFCR) by carboxylesterase in the liver, then to 5´DFUR by cytidine deaminase, and finally to 5-FU in tumor tissue by pyrimidine nucleoside phosphorylase. TP, an angiogenic substance identical to the angiogenic agent “platelet derived endothelial cell growth factor” (PD-ECGF)[11,12], is required for the final activation step of the prodrug. TP has been found to be expressed in atherosclerotic plaques[13]. This fact could explain the higher risk in patients with a prior history of coronary disease.

Deficiency of dihydropyrimidine dehydrogenase (DPD), the rate-limiting enzyme in fluoropyrimidines catabolism, has been linked to toxic side effects of these drugs. The most prominent mutation of the DPD gene resulting in severe DPD deficiency is a G to A mutation in the GT 5’-splice recognition site of intron 14 (exon 14-skipping mutation). The corresponding mRNA lacks exon 14, and the enzymatic activity of the translated DPD protein is virtually absent (Figure 2).

Myocardial injury, thrombogenic effects, immunoallergic reaction, and ischemia secondary to coronary artery spasm have all been implicated in the mechanism of 5-FU-induced cardiac toxicity, although coronary spasm is thought to be the main one[14-17]. Capecitabine toxicity is thought to have the same etiology as 5-FU, although Capecitabine and its metabolites are minimally cytotoxic in vitro compared with 5-FU[18].

Coronary spasm is defined as an abnormal contraction of an epicardial coronary artery resulting in myocardial ischemia. The commonly associated manifestations of myocardial ischemia are oppressive chest pain and ST-segment alterations on the electrocardiogram[19]. However, the most sensitive marker of myocardial ischemia is the appearance of a wall motion abnormality, which can be detected by echocardiography[20].

Our patient presented with rest and exercise-induced angina, and the stress echocardiogram revealed exercise-induced cardiac ischemia in the territory of the right and anterior descending coronary arteries. The coronary angiography was normal, both in baseline conditions and during intracoronary ergonovine injection. The absence of epicardial coronary stenosis ruled out atherosclerotic coronary disease as the cause of ischemia. The expected finding in this case was ergonovine-induced coronary spasm, but it failed to occur. Sometimes the test is negative in patients with spontaneous spasm because the sensitivity of ergonovine to induce spasm is below 100%. Another explanation for the discrepancy between the exercise stress test and the angiographic findings is the occurrence of spasm at the microvascular level, in small coronary vessels.

In conclusion, capecitabine should be considered a drug with cardiotoxic potential even in the absence of prior cardiac history. It can induce coronary spasm at the macro or microvascular level.

Footnotes

S- Editor Wang J L- Editor Karam SM E- Editor Chen GJ

References
1.  Roth A, Kolaric K, Popovic S. Letter: Cardiotoxicity of 5-fluorouracil (NSC-19893). Cancer Chemother Rep. 1975;59:1051-1052.  [PubMed]  [DOI]
2.  Akhtar SS, Salim KP, Bano ZA. Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study. Oncology. 1993;50:441-444.  [PubMed]  [DOI]
3.  Meyer CC, Calis KA, Burke LB, Walawander CA, Grasela TH. Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy. 1997;17:729-736.  [PubMed]  [DOI]
4.  Twelves C, Wong A, Nowacki MP, Abt M, Burris H, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352:2696-2704.  [PubMed]  [DOI]
5.  Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998;34:1274-1281.  [PubMed]  [DOI]
6.  Aksoy S, Karaca B, Dinçer M, Yalçin S. Common etiology of capecitabine and fluorouracil-induced coronary vasospasm in a colon cancer patient. Ann Pharmacother. 2005;39:573-574.  [PubMed]  [DOI]
7.  Frickhofen N, Beck FJ, Jung B, Fuhr HG, Andrasch H, Sigmund M. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol. 2002;13:797-801.  [PubMed]  [DOI]
8.  Rizvi AA, Schauer P, Owlia D, Kallal JE. Capecitabine-induced coronary vasospasm--a case report. Angiology. 2004;55:93-97.  [PubMed]  [DOI]
9.  Schnetzler B, Popova N, Collao Lamb C, Sappino AP. Coronary spasm induced by capecitabine. Ann Oncol. 2001;12:723-724.  [PubMed]  [DOI]
10.  Walko CM, Lindley C. Capecitabine: a review. Clin Ther. 2005;27:23-44.  [PubMed]  [DOI]
11.  Matsushita S, Nitanda T, Furukawa T, Sumizawa T, Tani A, Nishimoto K, Akiba S, Miyadera K, Fukushima M, Yamada Y. The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors. Cancer Res. 1999;59:1911-1916.  [PubMed]  [DOI]
12.  Miyadera K, Sumizawa T, Haraguchi M, Yoshida H, Konstanty W, Yamada Y, Akiyama S. Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase. Cancer Res. 1995;55:1687-1690.  [PubMed]  [DOI]
13.  Boyle JJ, Wilson B, Bicknell R, Harrower S, Weissberg PL, Fan TP. Expression of angiogenic factor thymidine phosphorylase and angiogenesis in human atherosclerosis. J Pathol. 2000;192:234-242.  [PubMed]  [DOI]
14.  Burger W, Chemnitius JM, Metz MZ, Bing RJ. A model for the study of coronary spasm induced changes in cardiac metabolism. J Mol Cell Cardiol. 1985;17:917-930.  [PubMed]  [DOI]
15.  Kuzel T, Esparaz B, Green D, Kies M. Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. Cancer. 1990;65:885-889.  [PubMed]  [DOI]
16.  Shoemaker LK, Arora U, Rocha Lima CM. 5-fluorouracil-induced coronary vasospasm. Cancer Control. 2004;11:46-49.  [PubMed]  [DOI]
17.  Südhoff T, Enderle MD, Pahlke M, Petz C, Teschendorf C, Graeven U, Schmiegel W. 5-Fluorouracil induces arterial vasocontractions. Ann Oncol. 2004;15:661-664.  [PubMed]  [DOI]
18.  Budman DR, Meropol NJ, Reigner B, Creaven PJ, Lichtman SM, Berghorn E, Behr J, Gordon RJ, Osterwalder B, Griffin T. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol. 1998;16:1795-1802.  [PubMed]  [DOI]
19.  Kawano H, Ogawa H. Endothelial function and coronary spastic angina. Intern Med. 2005;44:91-99.  [PubMed]  [DOI]
20.  Fujii H, Yasue H, Okumura K, Matsuyama K, Morikami Y, Miyagi H, Ogawa H. Hyperventilation-induced simultaneous multivessel coronary spasm in patients with variant angina: an echocardiographic and arteriographic study. J Am Coll Cardiol. 1988;12:1184-1192.  [PubMed]  [DOI]